How Can the European Federation for Colposcopy Promote High Quality Colposcopy Throughout Europe?

Since its inception in 1998, the European Federation for Colposcopy (EFC) now comprises 26 member societies. Its principle aim is to promote high quality colposcopy throughout Europe with special emphasis on training, education and treatment. This review summarises EFC’s activities and achievements to date

Relative expression levels of UGT1A isoforms among multiple human tissue samples.

<p>Relative expression levels of UGT1A isoforms among multiple human tissue samples.</p

Supplementary Data from Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells

Supplementary Data from Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cell

Figure 1

<p>Expression of UGT1A isoforms among multiple human tissue samples. For each functional UGT1A isoform (A through I), an example for the PCR gels for expression in multiple human tissues together with molecular weight markers is shown.</p

VDR binding to <i>BMP2</i> promoter region in vitro.

<p>ChIP assays were performed on UMR-106 cell extracts using anti-VDR antibody with or without 1,25(OH)₂D₃ administration. Normal IgG was used as a negative control. DNA was precipitated with either anti-VDR antibody or normal IgG. The primer pairs of putative VDREs in rat <i>BMP2</i> promoter region (as described in “Materials and Methods”) were used to amplify the ChIP DNA fragments. A. The site of <i>BMP2</i> promoter region C and the two corresponding promoters (−2181 and −1452) based on the conserved sequence data in mouse. B. The results showed that VDR bind to <i>BMP2</i> promoter region C.</p

Histone modifications associated with <i>BMP2</i> expression.

<p>A. qRT-PCR of <i>BMP2</i> expression in BMSCs from SD rats treated with varying concentrations of TSA. B. qRT-PCR of <i>BMP2</i> expression in BMSCs from SD rats treated with varying concentrations of TSA followed by 1,25(OH)₂D₃. C. qRT-PCR of <i>BMP2</i> expression in BMSCs from GHS rats treated with varying concentrations of TSA. D. qRT-PCR of <i>BMP2</i> expression in BMSCs from GHS rats treated with varying concentrations of TSA followed by 1,25(OH)₂D₃. E. qRT-PCR of <i>BMP2</i> expression in UMR-106 cells treated with varying concentrations of TSA. F. qRT-PCR of <i>BMP2</i> expression in UMR-106 cells treated with varying concentrations of TSA followed by 1,25(OH)₂D₃. G. Antibody against acetyl-histone H3 was used to do ChIP assay on chromatin extracted from UMR-106 cells which were incubated with 1,25(OH)₂D₃ (together with or without TSA) or vehicle. The normal IgG was used as a negative control. Primer pairs designed for <i>BMP2</i> promoter region C were used in the PCR. (*, P<0.05; **, P<0.01).</p

Putative VDREs regions and corresponding primers used in ChIP assays.

<p>The start and end nucleotide positions are based on the Rat genome assembly version Baylor 3.4/rn4. Region G and Region H share one primer pair.</p

Activation of <i>BMP2</i> expression by DAC.

<p>A. qRT-PCR of <i>BMP2</i> expression in BMSCs from SD rats treated with varying concentration of DAC. B. qRT-PCR of <i>BMP2</i> expression in BMSCs from SD rats treated with varying concentrations of DAC followed by 1,25(OH)₂D_3. C. qRT-PCR of <i>BMP2</i> expression in BMSCs from GHS rats treated with varying concentrations of DAC. D. qRT-PCR of <i>BMP2</i> expression in BMSCs from GHS rats treated with varying concentrations of DAC followed by incubation with 1,25(OH)₂D₃. E. qRT-PCR of <i>BMP2</i> expression in UMR-106 cells treated with varying concentrations of DAC. F. qRT-PCR of <i>BMP2</i> expression in UMR-106 cells treated with varying concentrations of DAC followed by 1,25(OH)₂D₃. G. Bisulfate sequencing of <i>BMP2</i> promoter CpG island methylation in UMR-106 cells with 1,25(OH)₂D₃ administration and the CpG response site. The sequence is numbered relative to the translational start site. H. Antibody against H3K9me2 was used to do ChIP assay on chromatin extracted from UMR-106 cells which were incubated with 1,25(OH)₂D₃ or vehicle. The normal IgG was used as a negative control. Primer pairs designed for <i>BMP2</i> promoter region C were used in the PCR. (*, P<0.05; **,P<0.01).</p

Association between CYP4F2 polymorphisms and plasma α-tocopherol levels.

<p>Analyses were based on linear regression which assumed an additive effect of the 433V or 12G allele</p><p>on Vit E metabolism (e.g. assigning the M/M, M/V and V/V genotypes to 0, 1 and 2). The association</p><p>between baseline level and CYP4F2 polymorphisms was tested in all cases for each trial,</p><p>while the association during treatment was tested only in the patients treated with Vit E. The r values refer to correlation coefficients.</p

2×2 comparison of <i>BRAF</i> mutations frequency in frozen and FFPE tissue sections (n = 159).

<p>MT = Mutant-type.</p><p>WT = Wild type.</p><p>κ = κ coefficient.</p><p><i>P</i> = statistical power.</p>*<p> = 7 <i>BRAF</i> analysis in the FFPE tissues were failed in DS due to noisy sequencing data.</p